Postoperative patients
Conditions
Interventions
Dexmedetomidine group. The mixture solution of morphine (0.5 mg/ml) and dexmedetomidine(1.25 micro g/ml) in normal saline( total volume 160 ml) will be intravenously infused at a rate of 1mlhr as a PC
Sponsors
Hirota Kazuyoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Age older than 65 years, less than 90 years 2 Scheduled to undergo surgery for primary solid organ cancer under general anesthesia, with an expected duration of surgery longer than 2 hours 3 Planned to use patient-controlled intravenous analgesia (PCIA) after surgery 4 Provide written informed consent.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded. 1 Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis; 2 Preoperative radio- or chemotherapy; 3 Inability to communicate in the preoperative period because of coma, profound dementia or language barrier; 4 Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or STOP-Bang scoring model score 5 Brain injury or neurosurgery; 6 Preoperative left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker; 7 Severe hepatic dysfunction (Child-Pugh class C) or severe renal dysfunction (requirement of renal replacement therapy before surgery); 8 ASA classification IV or above.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of delirium within the first 5 days after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Early outcomes 1.1 Daily frequency of delirium during the first 5 days after surgery; 1.2 Length of stay in hospital after surgery; 1.3 Incidence of non-delirium complications with 30 days after surgery; 1.4 All-cause 30-day mortality; 1.5 Quality of life of 30-day survivors: assessed with WHOQOL-BREF 1.6 Cognitive function of 30-day survivors: assessed with TICS-m 1.7 RASS sedation score during postoperative days 1-5; 1.8 Cumulative morphine consumption during postoperative days 1-5; 1.9 NRS pain score during postoperative days 1-5; 1.10 NRS score of subjective sleep quality during postoperative days 1-5. 2 Long-term outcomes 2.1 2-year survival after surgery; 2.2 Survival rates at different time-points after surgery; 2.3 2-year recurrence-free survival after surgery; 2.4 Recurrence-free survival rates at different time-points after surgery; 2.5 Quality of life in 1- and 2-year survivors after surgery (assessed with WHOQOL-BREF) 2.6 Cognitive function in 1- and 2-year survivors after surgery (assessed with TICS-m) | — |
Countries
China, Japan
Contacts
Public ContactEiji Hashiba
Hirosaki University Hospital
Outcome results
None listed